Search

everythinglearnresearchcommunity

for

Search:↓

High and low doses of prednisolone helped 62% of children with severe alopecia regrow hair with some weight gain and mild acne as side effects.

Old treatments for other skin conditions showed promise for hair regrowth in mice with a hair loss condition.

The cause of alopecia areata is likely a mix of genetics, immune system issues, and environmental factors, with more research needed to understand it fully.

New treatments for hair loss are showing promise due to better understanding of genetics and the immune system.

Alopecia Areata is an autoimmune hair loss condition that needs more research for better treatments.

Effective treatments for severe alopecia areata are still lacking.

Alopecia areata has a complex genetic basis that was not fully understood as of 2001.

Alopecia areata causes hair loss due to an immune attack on hair follicles, influenced by genetics and environment.

Patients with severe alopecia areata have higher levels of MIF, which decrease after successful treatment.

Advanced therapies like gene, cell, and tissue engineering show promise for hair regrowth in alopecia, but their safety and effectiveness need more verification.

Simvastatin/ezetimibe did not effectively treat severe alopecia areata and caused side effects in some patients.

The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

Genetic factors affect hair loss, and molecular testing may help predict, diagnose, and treat it.

People with alopecia areata have higher rates of mental health issues, autoimmune diseases, and infections.

A Brazilian teenager with severe hair loss had total hair regrowth with no side effects after using tofacitinib.

Leflunomide and anthralin may effectively treat severe alopecia areata.

JAK inhibitors may help treat Alopecia Areata but need careful monitoring due to side effects.

The conditions alopecia areata, primary sclerosing cholangitis, and ulcerative colitis may be linked by shared autoimmune and cell death mechanisms.

Treating alopecia areata every 3 weeks with diphenylcyclopropenone is more effective than weekly treatments.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Rare changes in the KRT82 gene are linked to a higher risk of Alopecia Areata.

Tofacitinib improves nail conditions in patients with severe hair loss and does not affect hair regrowth.

Current research explores hair growth drugs, while future research aims for personalized treatments.

The AIRE gene variant rs2075876 is linked to a higher risk of alopecia areata in males.

Nonsteroid treatments for alopecia areata show promise but need more high-quality research.

Oral baricitinib and ruxolitinib are effective and safe for treating alopecia areata.

Both dermatologists and patients in Japan agree that treatment success for alopecia areata is having 20% or less scalp hair loss.

People with Alopecia Areata often have lower vitamin D levels, and vitamin D supplements might help treat it.